Shimizu Kazuyuki, Itoh Junji, Sugiura Isamu, Tsushita Keitaroh, Kosugi Hiroshi, Nagura Eiichi
Department of Medicine, Nagoya City Midori General Hospital.
Rinsho Ketsueki. 2006 Apr;47(4):303-9.
Measurement of serum free-light chains (FLCs) was performed using a recently developed immunoassay in 180 healthy individuals, 16 patients with multiple myeloma, and each 1 patient with Waldenström's macroglobulinemia, primary amyloidosis, or MGUS (monoclonal gammopathy of undetermined significance) to evaluate the clinical relevance of FLCs in the diagnosis and disease monitoring. Serum FLC levels of each patient were elevated compared with the levels of healthy individuals. The changes in FLC levels after treatment and at the time of relapse occurred earlier than those in serum immunoglobulin levels due to the short half-life of FLCs. Serum FLC levels were elevated in patients with Bence Jones type myeloma in spite of negative urinary immunoelectrophoresis. The serum FLC assay is a sensitive and useful tool for the diagnosis and monitoring of multiple myeloma and other B-cell proliferative disorders.
使用一种最近开发的免疫测定法对180名健康个体、16名多发性骨髓瘤患者以及各1名患有华氏巨球蛋白血症、原发性淀粉样变性或意义未明的单克隆丙种球蛋白病（MGUS）的患者进行血清游离轻链（FLC）检测，以评估FLC在诊断和疾病监测中的临床相关性。与健康个体的水平相比，每位患者的血清FLC水平均升高。由于FLC半衰期短，治疗后及复发时FLC水平的变化比血清免疫球蛋白水平的变化出现得更早。尽管尿免疫电泳呈阴性，但本-周蛋白型骨髓瘤患者的血清FLC水平仍升高。血清FLC检测是诊断和监测多发性骨髓瘤及其他B细胞增殖性疾病的一种敏感且有用的工具。
